Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.


Journal article


J rheumatol

Publication Date





2477 - 2480


Adolescent, Adult, Aged, Child, Child, Preschool, Clinical Trials as Topic, Fingers, Gastrointestinal Diseases, Glomerular Filtration Rate, Health Status, Humans, Kidney Diseases, Middle Aged, Outcome Assessment (Health Care), Quality of Life, Research Design, Scleroderma, Localized, Scleroderma, Systemic, Skin Ulcer